% | $
Quotes you view appear here for quick access.

Aeolus Pharmaceuticals Inc. Message Board

  • adspatz adspatz Dec 23, 2013 11:24 AM Flag

    Aeolus announces annual results

    Search for "SEC Live Filings Digest" to find out more.
    Filing in Focus: Aeolus 10-K, December 20, 2013
    Aeolus Pharmaceuticals Inc. (AOLS) announced its financial results for the full fiscal year 2013, posting a net loss of $3.21M, or $0.03 losses per share. The biotechnology company, which develops chemical compounds to counter radiological and chemical threats, receives a large portion of its funding from the U.S. Government. The company’s large decreases in revenue as well as research and development costs were due mostly to the timing of certain program items under the Biomedical Advanced Research and Development Authority (BARDA) contract. Aeolus continues to develop and refine its flagship AEOL 10150 compound, which could be used to the benefit of those exposed, or about to be exposed, to high doses of radiation during oncology treatment. President and CEO John McManus commented that progress of its 10150 compound was very encouraging and that 2014 will be yet another exciting year as more testing and results are published on the chemical’s effectiveness.

0.165-0.005(-2.94%)May 25 11:28 AMEDT